# Phase 2a Desipramine in Small Cell Lung Cancer and Other High-Grade Neuroendocrine Tumors

> **NCT01719861** · PHASE2 · TERMINATED · sponsor: **Joel Neal** · enrollment: 6 (actual)

## Conditions studied

- Small Cell Lung Cancer (SCLC)
- Neuroendocrine Tumors

## Interventions

- **DRUG:** Desipramine HCL

## Key facts

- **NCT ID:** NCT01719861
- **Lead sponsor:** Joel Neal
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-10
- **Primary completion:** 2014-05
- **Final completion:** 2015-05
- **Target enrollment:** 6 (ACTUAL)
- **Why stopped:** Lack of efficacy
- **Last updated:** 2017-04-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01719861

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01719861, "Phase 2a Desipramine in Small Cell Lung Cancer and Other High-Grade Neuroendocrine Tumors". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01719861. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*